Research Article

Effect of Plastrum Testudinis Extracts on the Proliferation and Osteogenic Differentiation of rBMSCs by Regulating p38 MAPK-Related Genes

Qi Shang^{1,2}, Xiang Yu^{1,2}, Hui Ren^{2,3}, Gengyang Shen^{1,2}, Wenhua Zhao^{1,2}, Zhida Zhang^{1,2}, Jinjing Huang^{1,2}, Peiyuan Yu^{1,2}, De Liang^{2,3}, Jingjing Tang^{1,3}, and Xiaobing Jiang^{1,4}

¹The First Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China

²Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou 510405, China

³Department of Spinal Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China

⁴Shanghai University of Chinese Medicine, Shanghai 200032, China

Correspondence should be addressed to Jingjing Tang; 249943192@qq.com and Xiaobing Jiang; spinedrjxb@sina.com

Received 16 December 2018; Accepted 20 February 2019; Published 7 March 2019

Academic Editor: Mario Ledda

Copyright © 2019 Qi Shang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Extracts from plastrum testudinis (PTE) are active compounds that have been used to treat bone diseases in traditional Chinese medicine for thousands of years. In previous studies, we demonstrated their effects on glucocorticoid-induced osteoporosis both *in vivo* and *in vitro*. However, the mechanisms by which PTE regulates the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells (rBMSCs) *in vitro* remain poorly understood. In this study, rBMSCs were treated with medium (CON), PTE, osteogenic induction (OI), and a combination of PTE and OI (PTE+OI) over a 21-day period. We found that PTE significantly promoted rBMSCs osteogenic differentiation and mineralisation after 21 days of culturing. Moreover, PTE+OI further enhanced the differentiation and mineralisation process. PTE upregulated STE20, IGF1R, and p38 MAPK mRNA expression and downregulated TRAF6 mRNA expression. The extracts inhibited TRAF6 protein expression and promoted STE20, IGF1R, and phosphorylated p38 MAPK protein expression. Our results imply that PTE promotes the proliferation and osteogenic differentiation of rBMSCs by upregulating p38 MAPK, STE20, and IGF1R and downregulating TRAF6 expression, which may provide experimental evidence of the potential of PTE in the treatment of osteoporosis.

1. Introduction

Bone marrow-derived mesenchymal stem cells (BMSCs), which are multipotent cells with self-renewal ability, exhibit directional differentiation under appropriate stimulation [1]. As BMSCs are easily extracted and exhibit differentiation potential, cultured BMSCs are widely used *in vitro* to evaluate factors that contribute to osteogenesis [2]. Previously, we reported the beneficial effect of the extracts from plastrum testudinis (PTE) in glucocorticoid-induced osteoporosis (GIOP) in the rat spine *in vivo* [3, 4]. Furthermore, previous studies have demonstrated that PTE could promote BMSCs proliferation [5–7]. However, the underlying mechanisms by which PTE promotes the proliferation and osteogenic differentiation of rBMSCs are still poorly understood.

Mitogen-activated protein kinases (MAPKs) consist of c-Jun N-terminal kinases (JNK), p38 MAPK, and extracellular signal-regulated kinases (ERK) [8]. The MAPK cascade is a well-studied signaling pathway that regulates BMSCs differentiation during skeletal development [9–11]. Specifically, the p38 MAPK signalling pathway plays a crucial role in the inflammatory response, cell cycle, cell differentiation, and apoptosis [12]. More importantly, it has been demonstrated that the p38 MAPK pathway plays a key role in cell proliferation and osteogenic differentiation [9, 13, 14].

Sterile20 gene (STE20) functions upstream of the p38 MAPK cascade, involved in bone mineralisation [15–17]. Insulin-like growth factor 1 receptor (IGF-1R) is an upstream regulator of the p38 MAPK signalling pathway [18] and subsequently regulates cell growth, apoptosis, mineralisation,

FIGURE 1: Culture and identification of BMSCs. (a) Changes of cell morphology of BMSCs after cultured at three passage under inverted phase contrast microscope (magnification, 50 $\times$; scale bars, 250 μ m). (b) Expressions of surface antigens (CD90, CD44, CD45, and CD11b/c) of BMSCs detected by flow cytometry.

differentiation, and osteogenesis via binding of the IGF-1 ligand [19]. Tumor necrosis factor receptor-associated factor 6 (TRAF6), which also occurs upstream of the p38 MAPK pathway, has been shown to play a crucial role in regulating NF- κ B signalling, thus inhibiting osteoblast function [20, 21]. Given that the p38 MAPK signalling pathway and its related genes (STE20, IGF-1R, and TRAF6) play an essential role in the process of bone formation, we speculate that PTE influence the proliferation and osteogenic differentiation of rBMSCs through p38 MAPK and its related genes.

In this study, we investigated the effect of PTE on rBMSCs proliferation and osteogenic differentiation and examined the mechanism underlying p38 MAPK and its related genes in PTE-induced osteogenesis.

2. Results

2.1. Culture and Characterisation of rBMSCs. rBMSCs were cultured and purified *in vitro*. After culturing for 48h, numerous adherent cells could be seen. The majority of the cells displayed long spindle-like morphology. After three passages, the size of cell colony significantly increased, and the cells presented a spindle-like form (Figure 1(a)). Flow cytometry analysis was performed to investigate the surface antigen markers of the cultured cells. The cells were CD44- and CD90-positive and negative for CD11b/c and CD45 (Figure 1(b)). Taken together, these results indicated that the isolated adherent cells were phenotypically equivalent to typical rBMSCs.

FIGURE 2: Effect on rBMSCs proliferation of PTE was analysed at the 1st, 3th, 5th, 7th, and 14th day. The values of OD 450 were measured at the specific time points. The data were expressed as mean $\pm$ SD. **P < 0.01 and ***P < 0.001 versus the 0 ug/ml (control group).

2.2. PTE Promoted rBMSCs Proliferation. rBMSCs proliferation was examined at 1, 3, 5, 7, and 14 days (Figure 2). The relative cell numbers evaluated by the optical density (OD) value at each concentration of PTE gradually increased from the first to the seventh day. Furthermore, higher OD values were observed in groups to which PTE had been applied than in the control group (0 μ g/mL). Additionally, rBMSCs proliferation showed a steady slight decrease at a concentration of 30 μ g/mL PTE on the 14th day. Therefore, we

FIGURE 3: Osteogenic differentiation assay of rBMSCs. (a) The ALP staining assay of rBMSCs treated with PTE, osteogenic induction medium, and the combination of PTE and osteogenic induction medium at 21th day (magnification, 50×; scale bar, 100 μ m). (b) Quantitative assay of ALP staining. The data were expressed as mean $\pm$ SD. * p <0.05 versus control group, # p <0.05 versus PTE group, and ▲ p <0.05 versus OI group.

FIGURE 4: Osteogenic differentiation assay of rBMSCs. (a) The Alizarin red staining assay of rBMSCs treated with PTE, osteogenic induction medium, and the combination of PTE and osteogenic induction medium at the 21th day (magnification, 50×; scale bar, 100 μ m). (b) Quantitative assay of Alizarin red staining. The data were expressed as mean $\pm$ SD. * p <0.05 versus control group, # p <0.05 versus PTE group, and ▲ p <0.05 versus OI group.

selected a concentration of 30 μ g/mL PTE for the subsequent experiment.

2.3. PTE Promoted Osteogenic Differentiation of rBMSCs. To investigate the differentiation of rBMSCs stimulated by PTE, osteogenic induction medium (OI), the combination of PTE and osteogenic induction medium (PTE+OI) and the activity of alkaline phosphatase (ALP), a marker of osteogenesis, were also examined after 21 days of osteogenic differentiation (Figure 3). After 21 days of culturing, the PTE, OI, and PTE+OI groups all showed significantly stronger ALP staining compared to the control group, with the PTE+OI group exhibiting the strongest ALP staining.

Additionally, Alizarin red staining was performed at day 21 to evaluate the osteogenic mineralisation ability of rBMSCs after applying PTE, OI, and PTE+OI (Figure 4). After 21 days,

mineralized nodules had formed all three groups, with the highest matrix mineralisation in the PTE+OI group.

2.4. PTE Up-Regulated STE20, IGF1R, and p38 MAPK mRNA Expression, and Down-Regulated TRAF6 mRNA Expression. The relative mRNA expression of STE20 was significantly higher in the PTE group than in the control group at four time points. The relative mRNA expressions of IGF1R and p38 MAPK were upregulated in PTE group compared to those in the control group on days 3, 7, 14, and 21, whereas the relative mRNA expression of TRAF6 was downregulated at all four time points in the PTE group compared to the control group. Additionally, after osteogenic induction, the relative mRNA expressions of STE20, IGF1R, and p38 MAPK were upregulated at all four time points in the OI+PTE group. In contrast, the relative mRNA expression of TRAF6 was

FIGURE 5: The relative mRNA expressions of STE20, TRAF6, IGF1R, and p38 MAPK were shown at the 3th, 7th, 14th, and 21th day. The data are expressed as mean $\pm$ SD. * P <0.05 versus Con group; ** P <0.01 versus Con group; *** P <0.001 versus Con group.

generally downregulated in the OI+PTE group (Figures 5 and 6).

2.5. PTE Upregulated STE20, IGF1R, and p-P38 MAPK Protein Expression and Downregulated TRAF6 Protein Expression. After osteogenic induction at 14 and 21 days, the protein expressions of STE20, IGF1R, and p-P38 in all three groups, PTE, OI, and OI+PTE, were significantly upregulated compared to the control group. Conversely, TRAF6 protein expression was downregulated compared to the control group during rBMSCs osteogenic differentiation (Figure 7).

3. Discussion

The skeleton is a highly dynamic tissue whose structure relies on the balance between bone deposition and resorption [22]. Currently, most of the drugs available for osteoporosis are aimed at inhibiting osteoclastic bone resorption, and only a few drugs promote osteoblastic bone formation [23]. Therefore, it is becoming increasingly important to identify the factors that regulate bone formation and to develop new drugs that promote this process. PTE extracts are active

compounds of *plastrum testudinis*, which have been used to treat bone diseases in traditional Chinese medicine for thousands of years.

In our study, we explored the preliminary mechanism underlying the promotion of the osteogenic differentiation of rBMSCs by PTE. As the culture medium plays an important role in cell differentiation, we examined the PTE-promoted osteogenesis of rBMSCs in osteogenic medium. rBMSCs cultured in normal medium with PTE and in OI with PTE showed increased ALP activity and calcium deposition at 21 days, indicating that PTE promoted the osteogenic differentiation of rBMSCs and that PTE combined with OI had a synergistic effect on differentiation and mineralisation, which was consistent with our previous study [7]. Furthermore, to investigate the underlying mechanism, we examined the mRNA and protein expression of p38 MAPK and its related genes (STE20, IGF1R, and TRAF6) at different time point during rBMSCs osteoblast differentiation.

Previous studies have reported the crucial role of p38 MAPK in bone formation *in vivo* [24]. Attenuation of p38 MAPK phosphorylation *in vitro* inhibited osteoblast migration and differentiation [25–27]. In our study, we used

FIGURE 6: The relative mRNA expressions of STE20, TRAF6, IGF1R, and p38 MAPK were shown at the 3th, 7th, 14th, and 21th day. The data are expressed as mean $\pm$ SD. * P <0.05 versus OI group; ** P <0.01 versus OI group; *** P <0.001 versus OI group.

quantitative polymerase chain reaction (QT-PCR) assays to show that PTE upregulated p38 MAPK expression and Western blot analysis to show that it upregulated p38 MAPK phosphorylation, indicating that PTE promotes osteoblast differentiation via p38 MAPK. Additionally, we examined several genes related p38 MAPK for further confirmation of this process.

MAPK signalling pathways alter the expression, localisation, binding ability, and stability of transcriptional regulators [12]. The various MAPK pathways share a common family of upstream mediators such as STE20, IGF1R, and TRAF6. The STE20 kinases function as MAP4Ks, triggering activation of the MAPK cascade, which can activate p38 MAPK [28]. Furthermore, it has been reported that STE20 is a regulator of bone mineralisation [17]. IGF-1, whose receptor is IGF1R, was shown to be essential for matrix biosynthesis to sustain mineralisation and to play an important anabolic role in stimulating bone formation and maintaining bone mass [29]. A decrease in IGF-1R expression caused decreases in the amount of phosphorylated p38 MAPK and inhibited the p38 MAPK signalling pathway [18, 30]. Furthermore, mutation of

IGF1R correlated with a striking reduction in bone volume and trabecular number and an increase in trabecular spacing [29]. TRAF6 was shown to activate NF- κ B signalling, which suppressed osteoblast function and promoted osteoclast formation [20]. Additionally, a decrease in TRAF6 resulted in an increase in the number of osteoblasts [31]. In our study, we observed increased expression of IGF1R and STE20 and decreased expression of TRAF6, implying that PTE promotes the proliferation and osteogenic differentiation of rBMSCs by regulating p38 MAPK-related genes and proteins such as STE20, IGF1R, and TRAF6 (Figure 8).

4. Materials and Methods

4.1. Cell Isolation and Culture. rBMSCs were obtained from a 2-week-old Sprague-Dawley (SD) male rat. Bone marrow was flushed out of the femur and tibia with SD rBMSC basal medium (Cyagen, Guangzhou, China) supplemented with 10% (v/v) Sprague-Dawley (SD) rBMSC cell-qualified Fetal Bovine Serum, 1% (v/v) penicillin-streptomycin (Cyagen, Guangzhou, China), and 1% (v/v) glutamine in standard

FIGURE 7: Protein expression levels of TRAF6, STE20, IGF1R, and p-p38 MAPK were analysed by Western Blot. The data are expressed as mean $\pm$ SD. * P <0.05 versus control group, # P <0.05 versus PTE group, and Δ P <0.05 versus OI group.

sterile condition. Cells were plated and then incubated in a humidified atmosphere of 5% CO₂ at 37°C. They were passaged every 3 days using 0.25% (w/v) trypsin-EDTA solution (Cyagen, Guangzhou, China). After the third or fourth passage, the cells were used in our experiments [32].

The rBMSCs were cultured in an osteogenic induction medium (Cyagen, Guangzhou, China), composed of 175 mL SD rBMSC Basal Medium, 20 mL cell-qualified fetal bovine serum, 20 μ L dexamethasone, 400 μ L ascorbate, 2 mL glutamine, 2 mL penicillin-streptomycin, and 2 mL β -glycerophosphate, at an initial density of 2×10^4 cells/cm² (with 1 mL osteogenic induction medium per well) in 12 well plates to induce osteogenic differentiation. The medium was changed every 3 days during osteogenesis. The cells were observed under an inverted phase contrast microscope (Leica, Solms, Germany).

4.2. Cell Surface Marker Characterised by Flow Cytometry. The rBMSCs were characterised using flow cytometry.

Third-passage cells adherent to 80% confluence were selected, digested with 0.25% (w/v) trypsin-EDTA solution (Cyagen, Guangzhou, China), centrifuged at 250rcf for 5 min at 4°C, and suspended at 3×10^6 /mL using PBS containing 0.1% bovine serum albumin (BSA). Next, 100 μ L of the cell suspension was placed into 1.5 mL Eppendorf (each with 100 μ L). Monoclonal antibodies (CD90, CD44, CD45, and CD11b/c) (Cyagen, Guangzhou, China) from the rBMSCs were added to each Eppendorf, and mouse IgG1 was used as the isotype control antibody. After incubation in the dark at 4°C for 30 min, FITC-conjugated goat anti-mouse IgG (Cyagen, Guangzhou, China) was labelled with CD90, CD44, CD45, and CD11b/c; this was followed by incubation in the dark at 4°C for 30 min. Then, flow cytometry analysis was performed using a FACS Canto TM II Flow Cytometer (BD Bioscience, San Jose, CA, USA).

4.3. Preparation of *Plastrum Testudinis* Extracted with Ethylacetate. PTE extracts were obtained according to a previously established method [5]. The concentrations of PTE used in

FIGURE 8: Schematic of PTE on proliferation and osteogenic differentiation of rBMSCs by regulating p38 MAPK-related genes based on our findings.

the study were 0 (as control group), 0.03, 0.3, 3, 30, and 300 $\mu\text{g/mL}$.

4.4. Cell Counting Kit 8 (CCK-8) Assay. rBMSCs with a density of 5,000 cells/well were seeded in 96 well plates and cultured in growth medium. The proliferation of rBMSCs was assessed with the cell counting kit-8 (Tokyo, Japan) by using an OD setting of 450 nm in the microplate reader (Varioskan Flash; Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's protocol [33].

4.5. Osteogenic Differentiation Protocol. The optimal concentration of PTE for inducing osteogenic differentiation was selected based on the results of the CCK8 assay. To induce osteogenic differentiation, rBMSCs were cultured in growth medium (Cyagen, Guangzhou, China) in 12-well cell culture plates (Corning, Shanghai, China), at a density of $2 \times 10^4/\text{cm}^2$ and incubated for 48h at 37°C under 5% CO_2 . Cells were divided into the following four groups: Group A: control group, which received rBMSC basal medium (Cyagen, Guangzhou, China); Group B: PTE group, which received rBMSC basal medium with PTE; Group C: OI group, which received osteogenic induction medium; and Group D: PTE+OI group, which received osteogenic induction medium with PTE.

4.6. Alkaline Phosphatase Assay. rBMSCs were harvested at 21 days and re-suspended in PBS (pH 7.4), followed by homogenisation with ultrasonication. After centrifugation, ALP activity in the supernatants was assessed using ALP detection kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), reading the absorbance value on the microplate reader at 520 nm. A BCA protein assay kit (Keygen, Nanjing, China) was used to assess total protein content, which was used for ALP activity normalisation.

4.7. Alizarin Red Staining. After culturing in osteogenic medium for 21 days, PBS (pH 7.4) was used to wash the rBMSCs. Then, 4% paraformaldehyde was used to fix the rBMSCs at room temperature for 30 min, followed by rinsing in distilled water and then incubation for 10 min at room temperature with 40 mM Alizarin red staining (pH 4.2) (Sigma-Aldrich, Darmstadt, Germany) incubated. Observation was performed under an inverted microscope (Olympus, Tokyo, Japan). Subsequently, quantitative analysis of mineralised nodule areas indicated by the Alizarin red staining was performed using Image J software (National Institute of Health, Maryland, USA).

4.8. Quantitative Real-Time PCR (qRT-PCR). rBMSCs were harvested for RNA extraction. Total RNA was isolated from

TABLE 1: Quantitative PCR primer sequences.

Gene	Forward (5'-3')	Reverse (5'-3')
TRAF6	TGACAATGAAATACTGCTGGAA	CACAGCCTTTATTTGGACACTT
p38 MAPK	GATATTTGGTCCGTGGGC	TGGCTTGGCATCCTGTTA
STE20	AACCAAGGACAGTGGCTCG	CTGGGCTTTCTGCTCTTCC
IGF1R	ACATCCGCAACGACTATCAG	TTGTAGAAGAGTTTCCAGCCAC
GAPDH	CCTCGTCTCATAGACAAGATGGT	GGGTAGAGTCATACTGGAACATG

the rBMSCs using Trizol reagents (Invitrogen, Carlsbad, CA, USA). Polymerase chain reaction (PCR) was performed using the SYBR Green PCR kit (Invitrogen, Carlsbad, California, USA) from Applied Biosystems. GAPDH was used for gene expression normalisation. The primer sequences in the experiment are described in Table 1. The $2^{-\Delta\Delta C_t}$ method was used to calculate the relative gene expression. All reactions were performed in triplicate.

4.9. Western-Blot Analysis. Protein extracts from cells were prepared in RIPA lysis buffer supplemented with a proteasome inhibitor (Beyotime, Haimen, China). Total proteins were separated by using 10% SDS-PAGE and then transferred to a PVDF membrane (Millipore, Shanghai, China). After blocking in 5% BSA for 1 h at room temperature, the membranes were incubated overnight at 4°C with antibodies specific to GAPDH (RC-5G5; 1:10000; KangChen Biotech, Shanghai, China), TRAF6 (ab33915; 1:8000; Abcam, Cambridge, UK), p-p38 MAPK (#4511; 1:1000; CST, Boston, USA), STE20 (ab155198; 1:3000; Abcam, Cambridge, UK), and IGF1R (ab79176; 1:2000; Abcam, Cambridge, UK). HRP goat anti-rabbit IgG (BA1054; 1:20000, Boster Biologic Technology, Wuhan, China) was used as a secondary antibody for 2 h at room temperature. The signal intensity was quantified using Image J software (National Institute of Health, Bethesda, Maryland, USA).

4.10. Statistical Analysis. The data were analysed with SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). All results were expressed as means $\pm$ standard deviations (SDs). Comparisons between two groups were performed by Student's t-test, whereas comparisons among the groups were performed using one-way analysis of variance (ANOVA) with Turkey's post hoc test. Two-sided *P*-values < 0.05 were considered statistically significant.

5. Conclusion

Our results indicate that PTE could promote the proliferation and osteogenic differentiation of rBMSCs. Furthermore, the combination of PTE and osteogenic induction medium further enhanced osteogenic differentiation. Additionally, this study indicates that p38 MAPK and its related genes (STE20, IGF1R, and TRAF6) are involved in the mechanism of rBMSCs' osteogenic differentiation, which provides experimental evidence of the potential application of PTE in the treatment of osteoporosis. However, further research is necessary to elucidate the details of the upstream and downstream process of the p38 MAPK signalling pathway.

Furthermore, the application of advanced techniques, such as gene overexpression and knock-out studies, should be examined in future studies.

Abbreviations

PTE:	Plastrum testudinis extracts
rBMSCs:	Rat bone marrow-derived mesenchymal stem cells
OI:	Osteogenic induction
MAPK:	Mitogen-activated protein kinase
p-p38:	Phosphorylated p38
NF- κ B:	Nuclear factor- κ B
STE20:	Sterile20
IGF1R:	Insulin-like growth factor 1 receptor
TRAF6:	Tumor necrosis factor receptor-associated factor 6
ALP:	Alkaline phosphatase
GAPDH:	Glyceraldehyde 3-phosphate dehydrogenase
ARS:	Alizarin red staining.

Data Availability

The data used to support the findings of our study are available from the correspondences upon request.

Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Qi Shang, Xiang Yu, and Hui Ren contributed equally to this work. All authors listed in the current study carried out the experiments, participated in the design of the study, performed the statistical analysis, conceived of the study, and helped to draft the manuscript.

Acknowledgments

This work was generously supported by Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2018), National Natural Science Foundation of China (81674000, 81774338, and 81503591), Excellent Young Scholars Project of China Association of Traditional Chinese Medicine (CACM-2017-QNRC1-A02), Scientific Research Project of Guangdong Traditional Chinese Medicine Bureau (20191107), China Postdoctoral Science Foundation

(2017M610271), Excellent Doctoral Dissertation Incubation Grant of First Clinical School of Guangzhou University of Chinese Medicine (YB201602, YB201702), and Excellent Young Scholars Project of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (2017QN08, 2017TD08). The authors appreciate Professor Dongfeng Chen's help for providing the basis associated with extracts from *plastrum testudinis*. We also thank Lingnan Medical Research Center of Guangzhou University of Chinese Medicine for providing associated facilities.

References

- [1] A. Klimczak and U. Kozłowska, "Mesenchymal stromal cells and tissue-specific progenitor cells: their role in tissue homeostasis," *Stem Cells International*, vol. 2016, Article ID 4285215, 11 pages, 2016.
- [2] N. Artigas, C. Ureña, E. Rodríguez-Carballo, J. L. Rosa, and F. Ventura, "Mitogen-activated protein kinase (MAPK)-regulated interactions between osterix and Runx2 are critical for the transcriptional osteogenic program," *The Journal of Biological Chemistry*, vol. 289, no. 39, pp. 27105–27117, 2014.
- [3] D. Liang, H. Ren, T. Qiu et al., "Extracts from *plastrum testudinis* reverse glucocorticoid-induced spinal osteoporosis of rats via targeting osteoblastic and osteoclastic markers," *Biomedicine & Pharmacotherapy*, vol. 82, pp. 151–160, 2016.
- [4] H. Ren, G. Shen, J. Tang et al., "Promotion effect of extracts from *plastrum testudinis* on alendronate against glucocorticoid-induced osteoporosis in rat spine," *Scientific Reports*, vol. 7, no. 1, Article ID 10617, 2017.
- [5] D. F. Chen, H. P. Zeng, S. H. Du et al., "Extracts from *plastrum testudinis* promote proliferation of rat bone-marrow-derived mesenchymal stem cells," *Cell Proliferation*, vol. 40, no. 2, pp. 196–212, 2007.
- [6] T.-T. Wang, W. Chen, H.-P. Zeng, and D.-F. Chen, "Chemical components in extracts from *plastrum testudinis* with proliferation-promoting effects on rat mesenchymal stem cells," *Chemical Biology & Drug Design*, vol. 79, no. 6, pp. 1049–1055, 2012.
- [7] G.-Y. Shen, H. Ren, J.-J. Huang et al., "Plastrum testudinis extracts promote BMSC proliferation and osteogenic differentiation by regulating Let-7f-5p and the TNFR2/PI3K/AKT signaling pathway," *Cellular Physiology and Biochemistry*, vol. 47, no. 6, pp. 2307–2318, 2018.
- [8] G. L. Johnson and R. Lapadat, "Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases," *Science*, vol. 298, no. 5600, pp. 1911–1912, 2002.
- [9] L. E. Kokai, K. Marra, and J. P. Rubin, "Adipose stem cells: biology and clinical applications for tissue repair and regeneration," *Translational Research*, vol. 163, no. 4, pp. 399–408, 2014.
- [10] E. E. Puscheck, A. O. Awonuga, Y. Yang, Z. Jiang, and D. A. Rappolee, "Molecular biology of the stress response in the early embryo and its stem cells," *Advances in Experimental Medicine and Biology*, vol. 843, pp. 77–128, 2015.
- [11] Q. Du, D. Zhang, X. Chen et al., "The Effect of p38MAPK on Cyclic Stretch in Human Facial Hypertrophic Scar Fibroblast Differentiation," *Plos One*, vol. 8, no. 10, Article ID e75635, 2013.
- [12] C. Thouverey and J. Caverzasio, "Focus on the p38 MAPK signaling pathway in bone development and maintenance," *Bonekey Reports*, vol. 4, p. 711, 2015.
- [13] K. K. Ayyar and K. V. R. Reddy, "MAPK and NF- κ B signalling pathways regulate the expression of miRNA, let-7f in human endocervical epithelial cells," *Journal of Cellular Biochemistry*, vol. 119, no. 6, pp. 4751–4759, 2018.
- [14] R. Zhou, S. P. O'Hara, and X.-M. Chen, "MicroRNA regulation of innate immune responses in epithelial cells," *Cellular & Molecular Immunology*, vol. 8, no. 5, pp. 371–379, 2011.
- [15] P. Ling, T.-J. Lu, C.-J. Yuan, and M.-D. Lai, "Biosignaling of mammalian Ste20-related kinases," *Cellular Signalling*, vol. 20, no. 7, pp. 1237–1247, 2008.
- [16] S. Y. Leong, B. K. T. Ong, and J. J. H. Chu, "The role of Misshapen NCK-related kinase (MINK), a novel Ste20 family kinase, in the IRES-mediated protein translation of human enterovirus 71," *Plos Pathogens*, vol. 11, no. 3, Article ID e1004686, pp. 1–33, 2015.
- [17] G. Pathare, M. Föller, D. Michael et al., "Enhanced FGF23 serum concentrations and phosphaturia in gene targeted mice expressing WNK-resistant spak," *Kidney and Blood Pressure Research*, vol. 36, no. 1, pp. 355–364, 2012.
- [18] W. Wang, D. Wen, W. Duan et al., "Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway," *Brain Research Bulletin*, vol. 139, pp. 203–210, 2018.
- [19] T. Qiu, J. L. Crane, L. Xie, L. Xian, H. Xie, and X. Cao, "IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition," *Bone Research*, vol. 6, no. 1, p. 5, 2018.
- [20] T. Wang, S. Li, D. Yi et al., "CHIP regulates bone mass by targeting multiple TRAF family members in bone marrow stromal cells," *Bone Research*, vol. 6, no. 1, p. 10, 2018.
- [21] C. H. Shen, J. Y. Lin, Y. L. Chang et al., "Inhibition of NKCC1 modulates alveolar fluid clearance and inflammation in ischemia-reperfusion lung injury via TRAF6-mediated pathways," *Frontiers in Immunology*, vol. 9, p. 2049, 2018.
- [22] E. Rodríguez-Carballo, B. Gámez, and F. Ventura, "p38 MAPK signaling in osteoblast differentiation," *Frontiers in Cell and Developmental Biology*, vol. 4, p. 40, 2016.
- [23] M. Viswanathan, S. Reddy, N. Berkman et al., "Screening to prevent osteoporotic fractures updated evidence report and systematic review for the US preventive services task force," *Journal of the American Medical Association*, vol. 319, no. 24, pp. 2532–2551, 2018.
- [24] M. B. Greenblatt, J.-H. Shim, W. Zou et al., "The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice," *The Journal of Clinical Investigation*, vol. 120, no. 7, pp. 2457–2473, 2010.
- [25] T. Kawabata, T. Otsuka, K. Fujita et al., "(-)-Epigallocatechin gallate but not chlorogenic acid suppresses EGF-stimulated migration of osteoblasts via attenuation of p38 MAPK activity," *International Journal of Molecular Medicine*, vol. 42, no. 6, pp. 3149–3156, 2018.
- [26] X. Li, Y. Zheng, Y. Zheng et al., "Circular RNA CDR1as regulates osteoblastic differentiation of periodontal ligament stem cells via the miR-7/GDF5/SMAD and p38 MAPK signaling pathway," *Stem Cell Research & Therapy*, vol. 9, no. 1, p. 232, 2018.
- [27] C. Thouverey and J. Caverzasio, "The p38a MAPK positively regulates osteoblast function and postnatal bone acquisition," *Cellular and Molecular Life Sciences*, vol. 69, no. 18, pp. 3115–3125, 2012.
- [28] Y. Yan and D. Merlin, "Ste20-related proline/alanine-rich kinase: a novel regulator of intestinal inflammation," *World Journal of Gastroenterology*, vol. 14, no. 40, pp. 6115–6121, 2008.

- [29] M. Zhang, S. Xuan, M. L. Bouxsein et al., "Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization," *The Journal of Biological Chemistry*, vol. 277, no. 46, pp. 44005–44012, 2002.
- [30] G. Liu, S. Ma, Y. Li et al., "Hsa-let-7c controls the committed differentiation of IGF-1-treated mesenchymal stem cells derived from dental pulps by targeting IGF-1R via the MAPK pathways," *Experimental & Molecular Medicine*, vol. 50, no. 4, p. 25, 2018.
- [31] X. Ma, Z. Xu, S. Ding, G. Yi, and Q. Wang, "Alendronate promotes osteoblast differentiation and bone formation in ovariectomy-induced osteoporosis through interferon-beta/signal transducer and activator of transcription 1 pathway," *Experimental and Therapeutic Medicine*, vol. 15, no. 1, pp. 182–190, 2018.
- [32] E. Akhan, D. Tuncel, and K. C. Akcali, "Nanoparticle labeling of bone marrow-derived rat mesenchymal stem cells: their use in differentiation and tracking," *BioMed Research International*, vol. 2015, Article ID 298430, 9 pages, 2015.
- [33] H. H. Liu, H. J. Peng, Y. Wu et al., "The promotion of bone regeneration by nanofibrous hydroxyapatite/chitosan scaffolds by effects on integrin-BMP/Smad signaling pathway in BMSCs," *Biomaterials*, vol. 34, no. 18, pp. 4404–4417, 2013.